Scynexis (SCYX) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
May 9, 2016 9:25 AM EDTJERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an update on recent operational and clinical developments.
The clinical development program for SCY-078, a novel and structurally distinct glucan synthase inhibitor, as a treatment for invasive, drug-resistant or difficult-to-treat fungal infections, is progressing and we... More
